20 March 2017 - 22 March 2017
CCIB Convention Centre, Barcelona, Spain
Abingdon Health will be attending Bio-Europe Spring 2017, a partnering conference bringing together European companies from biotech and pharma.
A complementary diagnostic lateral flow assay can assist therapeutic decision making alongside other companion diagnostics.
A lateral flow device can monitor levels of circulating biomarkers to help manage an existing patient condition or to predict when an episode may occur across a wide range of disease areas.
Where Therapeutic Monoclonal Antibodies (mAb) drugs are prescribed, a lateral flow test can provide a real-time quantitative measure of the mAb in patient samples to help optimise drug delivery. These rapid tests can also be used to monitor patient antibodies directed against the Therapeutic mAb (ADAs) to manage drug efficacy.
Abingdon Health’s experience of working with different markers and sample matrices across multiple industries means we have the expertise required to develop these complementary diagnostic lateral flow assays.
We offer single or multiplexed lateral flow assay development and manufacturing services in our GMP compliant and ISO 13485 accredited facilities. We have recently launched our FDA registered and CE marked lateral flow reader, the ADxLR5®. These assay and reader services are offered to a range of markets including clinical diagnostics, biopharmaceutical, food and animal health.
If you are a pharma company looking to add value to your therapeutic, a diagnostic company looking to extend your ELISA range, or have a novel diagnostic challenge where a lateral flow could help, Abingdon Health would be delighted to meet with you.
Tel: +44 (0) 1904 406080
© Abingdon Health 2019